BRCA2
BRCA2 is critical for DNA double-strand break repair via homologous recombination. Alterations are clinically relevant for cancer risk assessment and therapeutic selection, particularly for PARP inhibitor therapy.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where BRCA2 is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Breast Cancer Solid Tumor · Breast |
| |
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate |
| |
Ovarian Cancer Solid Tumor · Ovary |
| |
Pancreatic Cancer Solid Tumor · Pancreas |
| |
Prostate Cancer Solid Tumor · Prostate |
|
Approvals defined at the solid tumor level where BRCA2 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report BRCA2 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports BRCA2 as part of its biomarker panel.
Reports BRCA2 as part of its biomarker panel.
Reports BRCA2 as part of its biomarker panel.